GlobalData Healthcare

All articles by GlobalData Healthcare

1. Trials Delayed Due to Covid-19 Begin to Resume

   Since early March, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to…
   Read More…

   2 Jul
2. FDA may be risk-averse to grant emergency use for a Covid-19 vaccine; political pressure and hazy EUA standards are factors

   by Reynald Castaneda in London, with additional reporting by Jennifer C Smith The FDA’s revocation of chloroquine and hydroxychloroquine’s Emergency…
   Read More…

   2 Jul
3. Gilead’s remdesivir to commence Phase I trials as inhaled therapy to target mild Covid-19 patients

   On 22 June, Gilead announced that it will begin Phase I clinical trials for inhaled remdesivir in healthy volunteers, and…
   Read More…

   26 Jun
4. Dexamethasone, an unexpected drug, shows promise in treating Covid-19

   Currently, there are over 2,200 clinical trials trying to find a vaccine or a therapy for Covid-19. The National Institute…
   Read More…

   25 Jun
5. Alexander O’Leary Q&A: how are clinical trial sponsors’ outsourcing activities evolving?

   The global clinical trial market is vast, but what are the major operational challenges that you have noticed many pharmaceutical…
   Read More…

   24 Jun
6. CanSino’s, J&J’s Covid-19 vaccines may be stifled by pre-existing antibodies while AstraZeneca’s, ReiThera’s may need booster

   by Reynald Castaneda in London. Despite its advantages over other vaccine technologies for Covid-19, adenovirus vector vaccines are likely to…
   Read More…

   23 Jun
7. The UK leads Covid-19 clinical investigations in Europe

   As Europe has been significantly impacted by the Covid-19 pandemic, a substantial amount of clinical research is currently focused on…
   Read More…

   18 Jun
8. Myovant’s Phase III relugolix trial’s cardiovascular event reduction trend inconclusive

   by Reynald Castaneda in London. Myovant Sciences’ Phase III relugolix trial in castrate-sensitive prostate cancer reporting of a positive trend in…
   Read More…

   18 Jun
9. AstraZeneca’s Tagrisso divides on immediate adoption in adjuvant non-small cell lung cancer

   by Manasi Vaidya in New York. AstraZeneca’s Tagrisso (osimertinib) may not find widespread adoption in the adjuvant setting for non-small cell…
   Read More…

   18 Jun
10. Long-term efficacy data shows MDMA is effective for treating PTSD

    The Multidisciplinary Association for Psychedelic Studies (MAPS) is developing the first-in-class innovator drug midomafetamine (MDMA) for use in treating chronic…
    Read More…

    15 Jun